Selecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 Conference

WATERTOWN, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., and Chief Financial Officer, Brad Dahms, will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 6 a.m. EST on Monday, January 11, 2021.

A webcast will also be available in the section of the company’s website at .

About Selecta Biosciences, Inc.

Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit .

For Investors:

Bruce Mackle

LifeSci Advisors, LLC

For Media:

Meredith Sosulski, Ph.D.

LifeSci Communications, LLC